> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Joint Panel to Review Sage Postpartum Depression Drug
- URL: https://www.fdaweb.com/joint-panel-to-review-sage-postpartum-depression-drug/
- Published: 2018-09-26T12:00:00.000Z
- Updated: 2026-09-15T00:34:19.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5142445

*Federal Register* notice: FDA has announced an 11/2 joint Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee meeting. Panel members are scheduled to discuss the efficacy, safety, and benefit-risk profile of a Sage Therapeutics NDA for brexanolone 5 mg/mL intravenous injection, indicated for postpartum depression. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2018-09-26/pdf/2018-20908.pdf?ref=fdaweb.com).